The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Glycated Albumin Is a Better Glycemic Indicator than Glycated Hemoglobin Values in Hemodialysis Patients with Diabetes: Effect of Anemia and Erythropoietin Injection
Abstract
The significance of glycated albumin (GA), compared with casual plasma glucose (PG) and glycated hemoglobin (HbA(1c)), was evaluated as an indicator of the glycemic control state in hemodialysis (HD) patients with diabetes. The mean PG, GA, and HbA(1c) levels were 164.5 +/- 55.7 mg/dl, 22.5 +/- 7.5%, and 5.85 +/- 1.26%, respectively, in HD patients with diabetes (n = 538), which were increased by 51.5, 31.6, and 17.7%, respectively, compared with HD patients without diabetes (n = 828). HbA(1c) levels were significantly lower than simultaneous PG and GA values in those patients in comparison with the relationship among the three parameters in patients who had diabetes without renal dysfunction (n = 365), as reflected by the significantly more shallow slope of regression line between HbA(1c) and PG or GA. A significant negative correlation was found between GA and serum albumin (r = -0.131, P = 0.002) in HD patients with diabetes, whereas HbA(1c) correlated positively and negatively with hemoglobin (r = 0.090, P = 0.036) and weekly dose of erythropoietin injection (r = -0.159, P < 0.001), respectively. Although PG and GA did not differ significantly between HD patients with diabetes and with and without erythropoietin injection, HbA(1c) levels were significantly higher in patients without erythropoietin. Categorization of glycemic control into arbitrary quartile by HbA(1c) level led to better glycemic control in a significantly higher proportions of HD patients with diabetes than those assessed by GA. Multiple regression analysis demonstrated that the weekly dose of erythropoietin, in addition to PG, emerged as an independent factor associated with HbA(1c) in HD patients with diabetes, although PG but not albumin was an independent factor associated with GA. In summary, it is suggested that GA provides a significantly better measure to estimate glycemic control in HD patients with diabetes and that the assessment of glycemic control by HbA(1c) in these patients might lead to underestimation likely as a result of the increasing proportion of young erythrocyte by the use of erythropoietin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 1×
“GA acquires biologic properties that are linked to the pathogenesis of diabetic vascular complications (28,29), suggesting that GA not only is significant as an indicator of hyperglycemia (30,31) but also contributes directly to vascular injury.”
BackgroundTurner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Correlation of Glucose Regulation and Hemoglobin AIcin Diabetes Mellitus
Koenig, R. J., Peterson, C. M., Jones, R. L., Saudek, C., Lehrman, M., & Cerami, A. (1976) · New England Journal of Medicine · doi:10.1056/nejm197608192950804 · Cited by 1,175
The Glycosylation of Hemoglobin: Relevance to Diabetes Mellitus
Bunn, H. F., Gabbay, K. H., & Gallop, P. M. (1978) · Science · doi:10.1126/science.635569 · Cited by 876
Pisoni, R. L., Bragg-Gresham, J. L., Young, E. W., Akizawa, T., Asano, Y., Locatelli, F., Bommer, J., Cruz, J. M., Kerr, P. G., Mendelssohn, D. C., et al. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.03.023 · Cited by 391
Cited by
Human serum albumin: From bench to bedside
Fanali, G., di Masi, A., Trezza, V., Marino, M., Fasano, M., & Ascenzi, P. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.12.002 · Cited by 1,931
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Diabetic kidney disease: a report from an ADA Consensus Conference
Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., et al. (2014) · Diabetes Care · doi:10.2337/dc14-1296 · Cited by 1,153
“Unlike A1C and other glycemic biomarkers, GA is less affected by low eGFR, anemia, or other confounding conditions (70).”
Diabetic Kidney Disease: A Report From an ADA Consensus Conference
Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.08.001 · Cited by 890
Diabetic Microvascular Disease: An Endocrine Society Scientific Statement
Barrett, E. J., Liu, Z., Khamaisi, M., King, G. L., Klein, R., Klein, B. E. K., Hughes, T. M., Craft, S., Freedman, B. I., Bowden, D. W., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01922 · Cited by 515
The glycation of albumin: Structural and functional impacts
Rondeau, P., & Bourdon, E. (2011) · Biochimie · doi:10.1016/j.biochi.2010.12.003 · Cited by 433
Pitfalls in Hemoglobin A1c Measurement: When Results may be Misleading
Radin, M. S. (2014) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2595-x · Cited by 361
Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis
Peacock, T. P., Shihabi, Z. K., Bleyer, A. J., Dolbare, E. L., Byers, J. R., Knovich, M. A., Calles-Escandon, J., Russell, G. B., & Freedman, B. I. (2008) · Kidney International · doi:10.1038/ki.2008.25 · Cited by 323
“A relative reduction in HbA1c among Japanese patients with type 2 diabetes on hemodialysis was reported by Inaba et al.(8) The % GA/HbA1c ratio was 2.”
BackgroundResultInfluentialClinical impact of glycated albumin as another glycemic control marker
Koga, M., & Kasayama, S. (2010) · Endocrine Journal · doi:10.1507/endocrj.k10e-138 · Cited by 290
Freedman, B. I., Shenoy, R. N., Planer, J. A., Clay, K. D., Shihabi, Z. K., Burkart, J. M., Cardona, C. Y., Andries, L., Peacock, T. P., Sabio, H., et al. (2010) · Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis · doi:10.3747/pdi.2008.00243 · Cited by 121
“An important limitation of this and the prior Japanese report (6) relates to recent glucose control being based upon the mean of three monthly serum glucose concentrations over the preceding 90 days.”
BackgroundMethodInfluentialRelationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease
Freedman, B. I., Shihabi, Z. K., Andries, L., Cardona, C. Y., Peacock, T. P., Byers, J. R., Russell, G. B., Stratta, R. J., & Bleyer, A. J. (2010) · American Journal of Nephrology · doi:10.1159/000287561 · Cited by 90
Influence of proteinuria on glycated albumin values in diabetic patients with chronic kidney disease
Okada, T., Nakao, T., Matsumoto, H., Nagaoka, Y., Tomaru, R., Iwasawa, H., & Wada, T. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.4129 · Cited by 81
“Although GA has been shown to be more accurate in the assessment of glycemic control than HbA1c in diabetic dialysis patients (6-8), it is not clear whether GA is also valid to assess diabetic predialysis CKD patients.”
BackgroundMeasurement of Hba1C in patients with chronic renal failure
Little, R. R., Rohlfing, C. L., Tennill, A. L., Hanson, S. E., Connolly, S., Higgins, T., Wiedmeyer, C. E., Weykamp, C. W., Krause, R., & Roberts, W. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.12.022 · Cited by 77
Glycated hemoglobin and outcomes in patients with advanced diabetic chronic kidney disease
Kuo, I.-C., Lin, H. Y.-H., Niu, S.-W., Hwang, D.-Y., Lee, J.-J., Tsai, J.-C., Hung, C.-C., Hwang, S.-J., & Chen, H.-C. (2016) · Scientific Reports · doi:10.1038/srep20028 · Cited by 70
Minimizing Glycemic Fluctuations in Patients with Type 2 Diabetes: Approaches and Importance
Dandona, P. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0372 · Cited by 67
Jung, M., Warren, B., Grams, M., Kwong, Y. D., Shafi, T., Coresh, J., Rebholz, C. M., & Selvin, E. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12618 · Cited by 43
Copur, S., Siriopol, D., Afsar, B., Comert, M. C., Uzunkopru, G., Sag, A. A., Ortiz, A., Covic, A., van Raalte, D. H., Cherney, D. Z., et al. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01581-x · Cited by 38
Williams, M. E., Mittman, N., Ma, L., Brennan, J. I., Mooney, A., Johnson, C. D., Jani, C. M., Maddux, F. W., & Lacson, E. (2015) · Hemodialysis International · doi:10.1111/hdi.12312 · Cited by 30
Metadata
- Authors
- Inaba, M., Okuno, S., Kumeda, Y., Yamada, S., Imanishi, Y., Tabata, T., Okamura, M., Okada, S., Yamakawa, T., Ishimura, E., & Nishizawa, Y.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2007-03
- Volume
- 18
- Issue
- 3
- Pages
- 896-903
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2114620129
- Cited by
- 493
- References
- 26
- FWCI
- 16.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.